KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

作者： Harry H. Yoon , David Tougeron , Qian Shi , Steven R. Alberts , Michelle R. Mahoney

关键词:

摘要: Purpose: We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined cetuximab a phase trial (N0147). Analysis was restricted to BRAF –wild-type tumors, because mutation associated poor prognosis, and are mutually exclusive. Experimental Design: The seven most common codon 12 13 were 2,478 tumors. Because ( n = 779) 220) not predictive benefit, study arms pooled for analysis. Disease-free survival (DFS) evaluated by HRs using Cox models. Results: (multivariate HR, 1.52; 95% confidence interval, CI, 1.28–1.80; P 0.0248) significantly shorter DFS compared wild-type / independent covariates. independently proficient mismatch repair Conclusion: either inferior resected cancer. These data highlight importance accurate molecular characterization significant role both codons progression this malignancy setting. Clin Cancer Res; 20(11); 3033–43. ©2014 AACR .

参考文章(51)

G. I Meling, P Laurent-Puig, B. J Iacopetta, R Glaesener, O. P. F Clausen, F Al-Mulla, W Giaretti, V. J Bubb, A. F. P. M de Goeij, G Gaudernack, T Ohkusa, P Quirke, A Rapallo, N Hawkins, R Rosell, T. O Rognum, S. N Andersen, R Smith, J Costa, R Ward, I Hoffmann, T Fujimori, D Cunningham, D Morton, C. T Croke, J Oates, X. F Sun, S Bell, P. A Clarke, S. T Wang, J Breivik, O Muller, A. R Norman, J. W Arends, M Pauly, D Dillon, H. J. N Andreyev, S. D Finkelstein, A. J Senagore, C. N Hall, K Wilkinson, N Lees, N. R Cruickshank, H. S Goh, D Snary, E Jullian, C Valavanis, L Losi, A Russo, H. M Rabes, J Piris, S Wadler, Y Ono, T Azuma, A Font, C Zietz, M Beranek, J. C Fox, S. A Halter, R Benamouzig, B. R Dix, H Zhang, C Faber, K Omura, V. E Pricolo, C Troungos, K Krtolica, J Benhattar, J. W. C Ho, N. Urosevic, T Lovig, D. P O'Donoghue, J. S Thebo, P De Angelis, J. Q Lee, J Young, Bazan, P Jandik, S Olschwang, S. T Yuen, T Walsh, S Malik, M Tanaka, Kirsten ras mutations in patients with colorectal cancer : the ‘RASCAL II’ study Faculty of Health; Institute of Health and Biomedical Innovation. ,vol. 85, pp. 692- 696 ,(2001)

Gabriel Capellà, Lourdes Farré, Isolda Casanova, Adela Mazo, Sílvia Guerrero, Ramon Mangues, K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Research. ,vol. 60, pp. 6750- 6756 ,(2000)

Jian Chen, Yun Ye, Haozhen Sun, Genming Shi, Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis Cancer Chemotherapy and Pharmacology. ,vol. 71, pp. 265- 272 ,(2013) , 10.1007/S00280-012-2005-9

Frank A. Sinicrope, Rafaela L. Rego, Megan M. Garrity-Park, Nathan R. Foster, Daniel J. Sargent, Richard M. Goldberg, Myron Wiesenfeld, Thomas E. Witzig, Stephen N. Thibodeau, Lawrence J. Burgart, Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability International Journal of Cancer. ,vol. 120, pp. 1232- 1238 ,(2007) , 10.1002/IJC.22429

Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535

Inti Zlobec, Michal Kovac, Priska Erzberger, Francesca Molinari, Michel P. Bihl, Alexander Rufle, Anja Foerster, Milo Frattini, Luigi Terracciano, Karl Heinimann, Alessandro Lugli, Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. International Journal of Cancer. ,vol. 127, pp. 2569- 2575 ,(2010) , 10.1002/IJC.25265

Peter H. Seeburg, Wendy W. Colby, Daniel J. Capon, David V. Goeddel, Arthur D. Levinson, Biological properties of human c-Ha-ras1 genes mutated at codon 12 Nature. ,vol. 312, pp. 71- 75 ,(1984) , 10.1038/312071A0

Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A

T Yokota, T Ura, N Shibata, D Takahari, K Shitara, M Nomura, C Kondo, A Mizota, S Utsunomiya, K Muro, Y Yatabe, BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer British Journal of Cancer. ,vol. 104, pp. 856- 862 ,(2011) , 10.1038/BJC.2011.19

10.

Chih-Chieh Chen, Tze-Kiong Er, Yen-Yi Liu, Jenn-Kang Hwang, Maria Jesus Barrio, Maximiliano Rodrigo, Enrique Garcia-Toro, Marta Herreros-Villanueva, None, Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations PLoS ONE. ,vol. 8, pp. e55793- ,(2013) , 10.1371/JOURNAL.PONE.0055793

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

来源期刊

我的账户

KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)

来源期刊

相似文章 10

我的账户